|
|
Article: Study Finds Life-Threatening Risks from Medication Errors in Hospitals Treating Pulmonary Hypertension Patients.
- Article from:
- Heart Disease Weekly
- Article date:
- November 22, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Pulmonary arterial hypertension (PAH) patients using infused drugs have suffered serious injury or in some cases died from medication errors in hospitals and other inpatient settings, according to a peer-reviewed study by Accredo Health Group and several university hospitals that surveyed doctors, nurses and pharmacists. The study, which was presented at the American College of Chest Physicians' annual meeting and will be published in the medical journal CHEST, examined medication errors for patients infused with epoprostenol (Flolan=AE) and treprostinil (Remodulin=AE) and provided guidelines to help reduce these risks (see also Pulmonary Hypertension).
Pulmonary ...
Related newspaper, magazine, and journal articles:
|
|
Article: Accredo Health, Inc. Announces Expiration of ...
Business Wire;
April 8, 2005 ;
700+ words
...MEMPHIS, Tenn. -- Accredo Health, Incorporated (NASDAQ: ACDO ... cash and stock transaction. Accredo Health, Incorporated provides specialized ... preliminary proxy statement of Accredo Health, Incorporated ("Accredo ...
|
|